Tag Archives | Drugs and Pharmaceuticals

Paragon BioTeck and Bausch + Lomb sign Exclusive License Agreement for Phenylephrine

MADISON, N.J. /eNewsChannels/ — NEWS Apr 19, 2013: Bausch + Lomb, the global eye health company and Paragon BioTeck, Inc. today announced that the companies have entered into a license agreement for Bausch + Lomb to commercialize and distribute Paragon’s phenylephrine in the United States on an exclusive basis beginning this month.

TOPICS: Business, News: Pharma, Newsdesk, State: New Jersey
 
» Continue Reading

Deanna Schwarz of Pfizer and CMI’s Paul Gondek and Alisa Hamilton to present at 2013 PRMG Annual National Conference

ATLANTA, Ga. /eNewsChannels/ — CMI and Pfizer Inc. (NYSE:PFE) will co-present ‘Engaging Stakeholders with A Story – 3 Tips to Improve Research Reporting’ at the PMRG’s upcoming National Annual Conference March 10-12, 2013 in National Harbor, Maryland.

TOPICS: Advertising, Business, Newsdesk, State: Georgia
 
» Continue Reading

Beth Thompson joins CMI as VP Qualitative Research, serving the Pharma Industries

ATLANTA, Ga. /eNewsChannels/ — CMI Research, a leader in marketing research services and insight, announced today that Beth Thompson has joined as Vice President, Qualitative Research. Thompson brings a 20-year track record of successfully conducting highly complex domestic and global marketing research.

TOPICS: Advertising, Business, Newsdesk, State: Georgia
 
» Continue Reading

Dermedics Laboratories to re-launch new version of Dr. Seltzer’s Hangover Helper

BRIDGEPORT, Conn. /eNewsChannels/ — In the early 1980’s George Coleman, head of Dermedics Laboratories in Bridgeport, Conn., teamed up with the former Keneric Industries to reformulate and market an over-the-counter pharmaceutical product designed to treat the symptoms of hangovers. The product, Dr. Seltzer’s Hangover Helper, went on to become the best-selling hangover remedy in the U.S. It was eventually sold to a well-known manufacturer and, after almost 20 years on the market, was discontinued when that manufacturer was sold.

TOPICS: Advertising, Business, Newsdesk, Retail, State: Connecticut, Videos
 
» Continue Reading

Compounded Medications Expert, Belvidere Pharmacy, Moves into Larger Facility in New Jersey

HIGHLAND PARK, N.J. /eNewsChannels/ — 2012 marks an important milestone for Belvidere Pharmacy. It opened new doors in its new hometown of Highland Park. When owner and President Shara Rudner, R.Ph. took the reins of the business in 1996, it was a typical retail pharmacy stocked with everything from school to surgical supplies. But from the beginning, Belvidere’s staff handled requests for compounded, or custom-made, medications from veterinarians, physicians and specialists.

TOPICS: Business, Newsdesk, State: New Jersey
 
» Continue Reading

Reaction Biology today announced the publication in Nature Biotechnology, of the largest kinase profiling data set in the public domain

MALVERN, Pa. /eNewsChannels/ — Reaction Biology Corporation (‘RBC’) today announced the publication in Nature Biotechnology, of the largest kinase profiling data set in the public domain, disclosing previously unknown kinase inhibition relationships. The data set was compiled from over 100,000 independent activity assays performed with RBC’s proprietary HotSpot(SM) technology.

TOPICS: Business, Medical, News: Pharma, Newsdesk, State: Pennsylvania
 
» Continue Reading

Recombinant Methyltransferase Line launched by Reaction Biology Corporation

MALVERN, Pa. /eNewsChannels/ — Reaction Biology Corporation (‘RBC’), a leading contract research organization providing drug discovery services in epigenetics, today announced the rollout of a new product line, recombinant proteins for epigenetic research. RBC’s initial offerings will emphasize the histone methyltransferases (HMTs), including exclusive targets for which there has been no previous commercial source.

TOPICS: Business, Medical, News: Product Launches, Newsdesk, State: Pennsylvania
 
» Continue Reading

REXIN-G, a Tumor-Targeted Genetic Medicine for Metastatic Cancer, Gains Phase 3 Product Designation from the U.S. FDA

SAN MARINO, Calif. /eNewsChannels/ — Epeius Bio announced today that the U.S. FDA has granted Phase 3 status for Company’s lead anti-cancer agent, Rexin-G, the first, and so far only, targeted gene delivery system developed to seek-out and destroy metastatic cancer.

TOPICS: Business, California, Medical, News: Pharma, Newsdesk
 
» Continue Reading

Belvidere Pharmacy has secured the coveted Pharmacy Compounding Accreditation Board’s Seal of Accreditation

NORTH PLAINFIELD, N.J. /eNewsChannels/ — For the second time in its history, Belvidere Pharmacy of North Plainfield has secured the coveted Pharmacy Compounding Accreditation Board’s (PCAB) Seal of Accreditation. Registered in New York, New Jersey and Connecticut, Belvidere was the first and is still the only accredited PCAB pharmacy in the New York metro area. It has held this distinction since 2007.

TOPICS: Business, Newsdesk, Retail, State: New Jersey
 
» Continue Reading

Epeius’ Rexin-G Gains U.S. Government Support as Therapeutic Discovery Project

SAN MARINO, Calif. /eNewsChannels/ — Epeius Biotechnologies Corporation, a leader in the emerging field of targeted genetic medicine, announced today the receipt of additional financial support for the company’s lead oncology product, Rexin-G, from the U.S. Departments of Treasury, Health and Human Services (HHS), and the National Institutes of Health (NIH) in the form of a prestigious competitive grant.

TOPICS: Business, California, Medical, Newsdesk
 
» Continue Reading

Reaction Bio Receives National Cancer Institute Grant for Epigenetic Platform

MALVERN, Pa. — Reaction Biology Corporation (RBC) announced today that it has been awarded a Phase II SBIR grant from the National Cancer Institute to expand the reach of its Methyltransferase HotSpot drug discovery platform. The $1.2 million, two-year grant will help fund an expansion of RBC’s methyltransferase screens from 14 to 35 or more.

TOPICS: Business, News: Pharma, Newsdesk, State: Pennsylvania
 
» Continue Reading

Epeius Tumor-targeted Gene Delivery Gains in Medicine and Patent Protection

SAN MARINO, Calif. — Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, received a notice of allowance from the USPTO for another crucial patent covering its leading tumor-targeted gene delivery platform. The issuance of this high-value patent protection for targeting metastatic disease follows on the heels of two major patent issuances.

TOPICS: Business, California, Medical, Newsdesk
 
» Continue Reading

ASCO 2010: Studies of Targeted Gene Delivery Confirm That Rexin-G Impacts Survival in Chemotherapy-resistant Bone and Soft Tissue Sarcoma

SAN MARINO, Calif. — Epeius Biotechnologies Corporation today announces the results of the clinical trial entitled ‘Advanced Phase I/II Evaluation of Tumor-Targeted Gene Delivery: Intravenous Rexin-G as Stand Alone Therapy for Chemotherapy-resistant Bone and Soft Tissue Sarcoma’ at the ASCO Annual Meeting on June 8, 2010. The presentation will be discussed by Dr. Kristen N. Ganjoo, Stanford University Medical Center, Palo Alto CA.

TOPICS: Business, California, Medical, Newsdesk
 
» Continue Reading

Epeius Tumor-Targeted Nanoparticle-based Gene Delivery Provides Evidence of Therapeutic Vaccination in Patients with Metastatic Cancer

SAN MARINO, Calif. — Epeius Biotechnologies Corporation today announces the clinical results of the study entitled ‘A Phase I/II Study of Intravenous Rexin-G and Reximmune-C for Cancer Immunotherapy: The GeneVieve Protocol’ at the ASCO Annual Meeting on June 6, 2010. The presentation will be made by Dr. Jorge G. Ignacio, Chairman of the Cancer Institute and Bioethics Committee-Philippine General Hospital, and Principal Investigator of the study.

TOPICS: Business, California, Medical, Newsdesk
 
» Continue Reading

Expert Reviews of Epeius Bio’s Targeted Genetic Medicine for Metastatic Cancer

SAN MARINO, Calif. — Epeius Biotechnologies Corporation, a leader in the field of targeted genetic medicine, reports the publication of three major publications in the field. The first article entitled ‘Rexin-G, A Targeted Genetic Medicine for Metastatic Cancer’ (Expert Opinion on Biological Therapy, May, 2010) documents the development of Rexin-G: a tumor-targeted retrovector bearing a cytocidal cyclin G1 construct; the first targeted gene therapy vector to gain FDA Fast Track designation and Orphan Drug priorities for multiple cancer indications in the USA.

TOPICS: Business, California, Medical, Newsdesk
 
» Continue Reading